Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab

被引：2
|
作者：
Zhang, Liyi [1 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
来源：
ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING | 2021年 / 8卷 / 04期
关键词：
FC-GAMMA RECEPTORS; MONOCLONAL-ANTIBODY; CHEMOTHERAPY; MGAH22;
D O I：
10.4103/apjon.apjon-2128
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
引用
收藏
页码：349 / 351
页数：3
相关论文
共 50 条
  • [31] Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer
    Creedon, Helen
    Byron, Adam
    Main, Joanna
    Hayward, Larry
    Klinowska, Teresa
    Brunton, Valerie G.
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2014, 42 : 822 - 830
  • [32] Estrogen receptor and human epidermal growth factor receptor-2 quantification and efficacy to trastuzumab
    Nuciforo, Paolo
    [J]. TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S569 - S571
  • [33] Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study
    Gligorov, Joseph
    Pivot, Xavier
    Ataseven, Beyhan
    De Laurentiis, Michelino
    Jung, Kyung Hae
    Manikhas, Alexey
    Azim, Hamdy Abdel
    Gupta, Kushagra
    Alexandrou, Ari
    Herraez-Baranda, Luis
    Tosti, Nadia
    Restuccia, Eleonora
    [J]. BREAST, 2022, 64 : 151 - 158
  • [34] Efficacy Analysis of Trastuzumab Combined With FLOT as Neoadjuvant Treatment of Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric Cancer
    Wu, K.
    Zheng, Y.
    Wang, Jiabao
    [J]. INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 84 : 267 - 271
  • [35] Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer
    Cripps, C.
    Winquist, E.
    Devries, M. C.
    Stys-Norman, D.
    Gilbert, R.
    [J]. CURRENT ONCOLOGY, 2010, 17 (03) : 37 - 48
  • [36] Human epidermal growth factor receptor 2 status in breast cancer: A comparison between borderline positive human epidermal growth factor receptor 2 and strongly positive human epidermal growth factor receptor 2 tumors
    Huszno, Joanna
    Nowara, Elibieta
    [J]. CLINICAL CANCER INVESTIGATION JOURNAL, 2015, 4 (03): : 307 - 311
  • [37] Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer
    Liberato, Nicola Lucio
    Marchetti, Monia
    Barosi, Giovanni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (06) : 625 - 633
  • [38] Efficacy of First-Line Treatment With Pertuzumab and Trastuzumab in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Routine Clinical Practice
    Camejo, Natalia
    Castillo, Cecilia
    Amarillo, Dahiana
    de los Santos, Heber
    Samurio, Gaston
    Silva-Marquez, Ahinara
    Sosa, Franco
    Vera, Claudia
    Xavier, Rocio
    Herrera, Guadalupe
    Alonso, Isabel
    Krygier, Gabriel
    [J]. WORLD JOURNAL OF ONCOLOGY, 2024, 15 (03) : 454 - 462
  • [39] Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
    Yu, Ke-Da
    Wang, Xin
    Chen, Wan-Kun
    Fan, Lei
    Mo, Miao
    Chen, Han
    [J]. NPJ PRECISION ONCOLOGY, 2020, 4 (01)
  • [40] Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
    Ke-Da Yu
    Xin Wang
    Wan-Kun Chen
    Lei Fan
    Miao Mo
    Han Chen
    [J]. npj Precision Oncology, 4
12345